Browse

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

DC Field Value Language
dc.contributor.authorGwak, G-Y-
dc.contributor.authorYoon, J-H-
dc.contributor.authorShin, C M-
dc.contributor.authorAhn, Y J-
dc.contributor.authorChung, J K-
dc.contributor.authorKim, Y A-
dc.contributor.authorKim, T-Y-
dc.contributor.authorLee, H-S-
dc.date.accessioned2010-01-06T06:42:12Z-
dc.date.available2010-01-06T06:42:12Z-
dc.date.issued2005-07-21-
dc.identifier.citationReceptor, Epidermal Growth Factor/*geneticsen
dc.identifier.issn0171-5216 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16032426-
dc.identifier.urihttps://hdl.handle.net/10371/26576-
dc.description.abstractPURPOSE: Epidermal growth factor receptor (EGFR) signalings have recently been implicated in the genesis and progression of cholangiocarcinomas. Thus, the EGFR kinase inhibitor appears to be promising in the treatment of this cancer. The response-predicting mutations in the tyrosine kinase domain of EGFR gene have recently been detected in non-small cell lung cancers. This study was, therefore, to investigate if these mutations are also found in cholangiocarcinomas. METHODS: Twenty-two consecutive cholangiocarcinoma patients who underwent surgical resection were enrolled. Their resected paraffin-embedded cholangiocarcinoma specimens were used for mutation analysis, which was performed by DNA sequencing of exons 18, 19 and 21 in the EGFR gene. Clinical characteristics were compared between each group according to the presence or absence of mutations. RESULTS: Three patients (13.6%) harbored EGFR mutations. All the mutations found were deletions in exon 19. Mutations were more common in intra-hepatic or poorly differentiated tumors. Differences in age, sex, stage at diagnosis and survival were not observed between mutation-positive and -negative patients. CONCLUSIONS: This study, for the first time, demonstrates that a subset of cholangiocarcinoma patients has response-predicting EGFR mutations. Therefore, a highly selected application of the EGFR kinase inhibitor would be therapeutically effective in these patients.en
dc.language.isoen-
dc.publisherSpringer Verlagen
dc.subjectAgeden
dc.subjectBase Sequenceen
dc.subjectBile Duct Neoplasms/*genetics/mortality/pathologyen
dc.subjectBile Ducts, Intrahepatic/*pathologyen
dc.subjectCholangiocarcinoma/*genetics/mortality/pathologyen
dc.subjectDNA Mutational Analysisen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMutationen
dc.subjectNeoplasm Stagingen
dc.subjectPhosphotransferases/*geneticsen
dc.subjectPrognosisen
dc.subjectReceptor, Epidermal Growth Factor/*geneticsen
dc.titleDetection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomasen
dc.typeArticleen
dc.identifier.doi10.1007/s00432-005-0016-1-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse